South Korea · Delayed Price · Currency is KRW CTCBIO Statistics
Total Valuation
CTCBIO has a market cap or net worth of KRW 78.30 billion. The enterprise value is 101.99 billion.
| Market Cap | 78.30B |
| Enterprise Value | 101.99B |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCBIO has 23.91 million shares outstanding. The number of shares has decreased by -1.17% in one year.
| Current Share Class | 23.91M |
| Shares Outstanding | 23.91M |
| Shares Change (YoY) | -1.17% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.17% |
| Float | 13.67M |
Valuation Ratios
The trailing PE ratio is 12.74.
| PE Ratio | 12.74 |
| Forward PE | n/a |
| PS Ratio | 0.61 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | 7.92 |
| P/OCF Ratio | 7.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.22, with an EV/FCF ratio of 10.32.
| EV / Earnings | 16.71 |
| EV / Sales | 0.79 |
| EV / EBITDA | 6.22 |
| EV / EBIT | 10.25 |
| EV / FCF | 10.32 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.62 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 2.34 |
| Debt / FCF | 3.89 |
| Interest Coverage | 4.44 |
Financial Efficiency
Return on equity (ROE) is 7.90% and return on invested capital (ROIC) is 9.10%.
| Return on Equity (ROE) | 7.90% |
| Return on Assets (ROA) | 4.21% |
| Return on Invested Capital (ROIC) | 9.10% |
| Return on Capital Employed (ROCE) | 9.92% |
| Weighted Average Cost of Capital (WACC) | 4.44% |
| Revenue Per Employee | 519.19M |
| Profits Per Employee | 24.62M |
| Employee Count | 248 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 2.49 |
Taxes
In the past 12 months, CTCBIO has paid 641.56 million in taxes.
| Income Tax | 641.56M |
| Effective Tax Rate | 9.49% |
Stock Price Statistics
The stock price has decreased by -52.67% in the last 52 weeks. The beta is -0.04, so CTCBIO's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -52.67% |
| 50-Day Moving Average | 3,776.60 |
| 200-Day Moving Average | 4,872.95 |
| Relative Strength Index (RSI) | 33.96 |
| Average Volume (20 Days) | 188,911 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CTCBIO had revenue of KRW 128.76 billion and earned 6.11 billion in profits. Earnings per share was 256.58.
| Revenue | 128.76B |
| Gross Profit | 52.18B |
| Operating Income | 9.95B |
| Pretax Income | 6.76B |
| Net Income | 6.11B |
| EBITDA | 16.39B |
| EBIT | 9.95B |
| Earnings Per Share (EPS) | 256.58 |
Balance Sheet
The company has 19.16 billion in cash and 38.39 billion in debt, with a net cash position of -19.23 billion or -804.48 per share.
| Cash & Cash Equivalents | 19.16B |
| Total Debt | 38.39B |
| Net Cash | -19.23B |
| Net Cash Per Share | -804.48 |
| Equity (Book Value) | 80.68B |
| Book Value Per Share | 3,179.70 |
| Working Capital | 28.55B |
Cash Flow
In the last 12 months, operating cash flow was 10.90 billion and capital expenditures -1.02 billion, giving a free cash flow of 9.88 billion.
| Operating Cash Flow | 10.90B |
| Capital Expenditures | -1.02B |
| Depreciation & Amortization | 6.44B |
| Net Borrowing | 6.76B |
| Free Cash Flow | 9.88B |
| FCF Per Share | 413.26 |
Margins
Gross margin is 40.52%, with operating and profit margins of 7.73% and 4.74%.
| Gross Margin | 40.52% |
| Operating Margin | 7.73% |
| Pretax Margin | 5.25% |
| Profit Margin | 4.74% |
| EBITDA Margin | 12.73% |
| EBIT Margin | 7.73% |
| FCF Margin | 7.67% |
Dividends & Yields
CTCBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.17% |
| Shareholder Yield | 1.17% |
| Earnings Yield | 7.80% |
| FCF Yield | 12.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 22, 2013. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 22, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
CTCBIO has an Altman Z-Score of 2.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.11 |
| Piotroski F-Score | 6 |